ObjectiveTo investigate the distribution characteristics and antimicrobial resistance of carbapenemresistant Acinetobacter baumannii  (CRAB), and to guide effective clinical prevention and rational antimicrobial  use.MethodsData about clinically isolated CRAB between January 2009 and December 2013 were analyzed retrospectively, distribution and antimicrobial resistance were analyzed by WHONET 5.5 software.ResultsA total of 888 Acinetobacter baumannii strains were isolated,421  of which were CRAB, the isolation rate was 47.4%, the isolation rates in 2011, 2012 and 2013 were all about 50.0%; CRAB strains were mainly isolated from sputum (73.4%) and mostly distributed in intensive care unit(ICU) (61.3%), followed by neurosurgery department(12.4%). CRAB presented highly antimicrobial resistance. Except cefotaxime and cefatriaxone, resistant rates of CRAB to the other detected antimicrobial agents(ceftazidime, cefepime, cefoperazone / sulbactam,aztreonam, imipenem, amikacin, gentamycin, minocycline, chloramphenicol, levofloxacin, ciprofloxacin, and compound sulfamethoxazole) were all higher than nonCRAB isolates( all P≤0.01), Compared with nonCRAB isolates, The resistant rate of CRAB to cefoperazone/sulbactam was the lowest(<15%), followed by minocycline, resistant rates to other antimicrobial agents were all >80.0%. ConclusionSurveillance of CRAB should be further strengthened. It is necessary to focus on the control and prevention of healthcareassociated infection in ICU patients and respiratory system. ［Key words］Acinetobacter baumannii; carbapenemase; carbapenemresistant antibiotic; carbapenemresistant Acinetobacter baumannii; drug resistance,microbial;healthcareassociated infection